Company intelligence / Profile preview

Accellix

Ownership: Private
Development stage: Commercial

Overview

The Accellix Platform enables rapid, automated multi-parametric cellular analysis at the point of need for GMP manufacturing and quality control in the cell and gene therapy industry. It streamlines sample preparation, data acquisition, and analysis into a single benchtop instrument using microfluidic cartridges with dried reagents. The technology has been adopted by major organizations such as the American Red Cross to improve source material characterization for allogeneic cell therapy development

Modalities: Device (Automated flow cytometry platform)Diagnostic device (for cell therapy QC)
Industry: Protein Biomarker Diagnostics

Partnerships

American Red Cross Cell and Gene Therapy Solutions division

Beyond the preview

Go deeper on Accellix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Accellix.

Explore the full profile